Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials

• The relative benefit of new antidiabetic drugs for cardiorenal endpoints is unclear. • The most efficacious drugs vary with different cardiorenal endpoints. • Subcutaneous semaglutide and albiglutide are most effective for cardiac events. • Canagliflozin and empagliflozin are most effective for he...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients. - 2016. - Amsterdam [u.a.]
1. Verfasser: Wei, Xu-Bin (VerfasserIn)
Weitere Verfasser: Wei, Wei (BerichterstatterIn), Ding, Liang-Liang (BerichterstatterIn), Liu, Shu-Yan (BerichterstatterIn)
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients
Schlagworte:CVD GLP-1 RAs ACD RCT KFP MACE CI HHF SUCRA HR mehr... MI SGLT2 inhibitors
Umfang:4
Beschreibung
Zusammenfassung:• The relative benefit of new antidiabetic drugs for cardiorenal endpoints is unclear. • The most efficacious drugs vary with different cardiorenal endpoints. • Subcutaneous semaglutide and albiglutide are most effective for cardiac events. • Canagliflozin and empagliflozin are most effective for heart failure hospitalization. • Dapagliflozin and empagliflozin are most effective for kidney function progression.
Beschreibung:4
DOI:10.1016/j.pcd.2020.08.017